Amicus Therapeutics (FOLD) Non-Current Deferred Tax Liability (2016 - 2022)
Amicus Therapeutics filings provide 10 years of Non-Current Deferred Tax Liability readings, the most recent being $4.9 million for Q4 2022.
- On a quarterly basis, Non-Current Deferred Tax Liability changed 0.18% to $4.9 million in Q4 2022 year-over-year; TTM through Dec 2022 was $4.9 million, a 0.18% change, with the full-year FY2022 number at $4.9 million, changed 0.18% from a year prior.
- Non-Current Deferred Tax Liability hit $4.9 million in Q4 2022 for Amicus Therapeutics, roughly flat from $4.9 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $6.5 million in Q1 2018 to a low of $4.9 million in Q4 2020.
- Median Non-Current Deferred Tax Liability over the past 5 years was $5.1 million (2019), compared with a mean of $5.5 million.
- Biggest five-year swings in Non-Current Deferred Tax Liability: plummeted 96.28% in 2018 and later increased 0.69% in 2021.
- Amicus Therapeutics' Non-Current Deferred Tax Liability stood at $6.5 million in 2018, then dropped by 21.87% to $5.1 million in 2019, then decreased by 3.07% to $4.9 million in 2020, then grew by 0.69% to $4.9 million in 2021, then increased by 0.18% to $4.9 million in 2022.
- The last three reported values for Non-Current Deferred Tax Liability were $4.9 million (Q4 2022), $4.9 million (Q3 2022), and $4.9 million (Q2 2022) per Business Quant data.